Swiss National Bank
PCVX icon

Swiss National Bank’s Vaxcyte PCVX Stock Holding History

Swiss National Bank’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3M Buy
245,500
+12,400
+5% +$673K 0.01% 848
2026
Q1 		$13.5M Buy
233,100
+2,700
+1% +$147K 0.01% 805
2025
Q4 		$10.6M Buy
230,400
+5,300
+2% +$237K 0.01% 943
2025
Q3 		$8.11M Buy
225,100
+3,800
+2% +$126K ﹤0.01% 1071
2025
Q2 		$7.19M Buy
221,300
+4,000
+2% +$131K ﹤0.01% 1087
2025
Q1 		$8.21M Sell
217,300
-1,700
-0.8% -$136K 0.01% 993
2024
Q4 		$17.9M Buy
219,000
+38,400
+21% +$3.81M 0.01% 679
2024
Q3 		$20.6M Sell
180,600
-700
-0.4% -$63.1K 0.01% 639
2024
Q2 		$13.7M Buy
181,300
+3,300
+2% +$225K 0.01% 749
2024
Q1 		$12.2M Buy
178,000
+30,100
+20% +$2.08M 0.01% 830
2023
Q4 		$9.29M Sell
147,900
-6,600
-4% -$343K 0.01% 921
2023
Q3 		$7.88M Buy
154,500
+5,500
+4% +$271K 0.01% 1010
2023
Q2 		$7.44M Buy
149,000
+29,700
+25% +$1.41M 0.01% 1066
2023
Q1 		$4.47M Sell
119,300
-6,400
-5% -$271K ﹤0.01% 1349
2022
Q4 		$6.03M Buy
125,700
+42,700
+51% +$1.68M ﹤0.01% 1202
2022
Q3 		$1.99M Buy
83,000
+3,400
+4% +$86.2K ﹤0.01% 1875
2022
Q2 		$1.73M Buy
79,600
+29,600
+59% +$685K ﹤0.01% 2022
2022
Q1 		$1.21M Buy
50,000
+4,100
+9% +$89.6K ﹤0.01% 2313
2021
Q4 		$1.09M Buy
45,900
+1,000
+2% +$23.3K ﹤0.01% 2431
2021
Q3 		$1.14M Hold
44,900
– – ﹤0.01% 2372
2021
Q2 		$1.01M Buy
44,900
+10,400
+30% +$213K ﹤0.01% 2477
2021
Q1 		$681K Hold
34,500
– – ﹤0.01% 2424
2020
Q4 		$917K Buy
+34,500
New +$1.28M ﹤0.01% 2336

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Swiss National Bank's PCVX Position: Q2 2026 in Review

Swiss National Bank increased its Vaxcyte (PCVX) stake by 5.3% in Q2 2026, buying an estimated $673K and bringing the position to 245,500 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #848.

Swiss National Bank first reported a position in PCVX in Q4 2020 and has held it in 23 quarters since. The position peaked at $20.6M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Swiss National Bank held 245,500 shares of Vaxcyte worth $14.3M as of Q2 2026.
  • Swiss National Bank bought 12,400 Vaxcyte shares in Q2 2026, an estimated $673K.
  • Vaxcyte made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #848 holding.
  • Swiss National Bank first reported a position in Vaxcyte in Q4 2020 and has held it in 23 quarters since.
  • Swiss National Bank's Vaxcyte position peaked at $20.6M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.